Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CD163 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

CD163 expression (1)

CD163 underexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

CD163 expression (1)

CD163 underexpression (1)

PD-L1 overexpression + CD163 underexpression (1)

›

CD163 overexpression	Hodgkin Lymphoma	CD163 overexpression	Hodgkin Lymphoma	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials nivolumab + brentuximab vedotin Sensitive : C3
CD163 overexpression	Solid Tumor	CD163 overexpression	Solid Tumor	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3	avelumab + eftilagimod alpha Sensitive: C3 – Early Trials avelumab + eftilagimod alpha Sensitive : C3
CD163 overexpression	Solid Tumor	CD163 overexpression	Solid Tumor	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3	eftilagimod alpha Sensitive: C3 – Early Trials eftilagimod alpha Sensitive : C3
CD163 overexpression	Bladder Cancer	CD163 overexpression	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3